Frank Leonard, Chief Executive Officer of NovoCure Limited (NASDAQ:NVCR), reported an open-market sale of 34,273 common shares for a transaction value of ~$615,000 on June 4, 2026, according to a SEC Form 4 filing.
Transaction summary Transaction value based on SEC Form 4 reported price ($17.93); post-transaction value based on June 4, 2026, market close ($17.99)
Key questions – How does the size of this transaction compare to prior open-market sales by Frank Leonard? This sale of 34,273 shares is the largest individual open-market sale reported by Frank Leonard to date, exceeding the prior maximum single-sale size of 30,196 shares. – What proportion of Frank Leonard’s direct NovoCure Limited holdings did this sale represent? The transaction accounted for 6.94% of his direct holdings at the time of sale, reducing them from 493,793 to 459,520 shares. – Were any indirect or derivative interests impacted by this trade?
No indirect or derivative holdings were affected; all shares sold were directly owned, and there were no changes in options or trust holdings. – Does this activity suggest a change in selling cadence or reflect available share capacity? While the sale size is elevated versus recent transactions, the reduction in holdings over the past year has lowered available capacity, and this larger sale size aligns with the remaining share base rather than a discretionary increase in selling pace. Company overview * 1-year performance is calculated using June 4th, 2026 as the reference date.